Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

PKvitality announces the results of its 3rd clinical trial on humans

Paris, July 26, 2022 – The French startup PKvitality, focusing on health and sport biowearables, is developing K’Watch Glucose, the first Continuous Glucose Monitor (CGM) in the form of a smartwatch, designed to change the daily lives of millions of diabetic patients. After two first phases of testing which brought a significant step forward on the initial roadmap, the company champion of innovation against diabetes announces the results of its third phase of clinical trials on humans (First-in-human).

PKvitality’s mission is to enable everyone to contribute actively to their well-being and health through products that are simple and comfortable to use. Thus, its K’Watch Glucose smartwatch will be the world’s first CGM device that will track glucose levels discreetly and continuously at the wrist. This system, currently at the stage of clinical studies, will measure the level of glucose in the interstitial fluid through micro-tips. It will thus offer a painless and non-stigmatizing experience to the user.

Related posts


Cibiltech announces the first patient enrolled in its international clinical trial for monitoring kidney transplant patients using artificial intelligence

PARIS–(BUSINESS WIRE)–Cibiltech announced today that the first patient has been enrolled in the CIBIL clinical trial “Clinical Impact of the iBox as an early Intervention tool”. A prospective randomized controlled trial to assess the use of a software predicting allograft survival in the follow-up of kidney transplanted patients (NCT05112315). This marks the beginning of this first-of-its-kind clinical trial conducted in Europe evaluating a digital health solution.

Read More »
Investment banking

PKvitality finalized its €6m Series A with a significant investment from EIC Fund

Paris, January 28, 2022 – PKvitality, a French company specializing in bio-wearables, finalized a funding round of €6m, including an investment from the EIC Fund (European Innovation Council Fund). Other contributors to this round are Business Angels, EIT Health, alongside current investors on board, including Beurer GmbH. This round will accelerate the development of K’Watch Glucose, a Continuous Glucose Monitor (CGM) embedded in a smartwatch for diabetes patients.

Read More »